Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acne Scars Wrinkle Atrophic Acne Scar Hypertrophic Scar Male or female in good general health, as determined by the Investigator, aged ≥18 and ≤75 at the time of consent. 2. Regions of suitable skin to be selected as Target Area(s), as determined by a physical examination conducted by the Investigator during a screening visit 1. Cohort 1 single region of healthy buttock skin; 2. Cohort 2 -two bilaterally symmetrical regions of shallow-to-moderately deep facial wrinkles; and 3. Cohort 3 two bilaterally symmetrical regions of moderate-to-severe atrophic acne scars. 3. A Fitzpatrick skin phototype score of I-IV. 4. A negative pregnancy test at the Study Day 0 Visit for subjects of child-bearing potential. 5. Signed and dated informed consent and willingness to attend all study visits and complete all procedures required by this protocol  Any transient or chronic skin condition, disorder, or infection within 20 cm of the Target Areas that, in the opinion of the Investigator, may confound study results. 2. History of laser treatment or chemical peels to the Target Areas within six months of the Study Day 0 Visit. 3. History of surgical procedures to Target Areas, including removal of benign or malignant skin cancers that, in the opinion of the Investigator, may confound study results. 4. Administration of a cosmetic and/or clinical research investigational agent, excluding KB301, in close proximity to the Target Areas within 12 months of the Study Day 0 Visit, that, in the opinion of the Investigator, may confound study results. 5. Any condition (including a history or current evidence of substance abuse or dependence) that, in the Investigator's opinion, would impact subject's ability to complete all study-related procedures and/or poses an additional risk to the assessment of safety of the Investigational Product. 6. An active oral herpes infection at the Screening Visit or Study Day 0 Visit. 7. Women who are pregnant or nursing. 8. Subject who is unwilling to comply with contraception requirements per protocol. 9. A history of anaphylaxis or allergic reactions to any of the constituents of the product and/or local anesthetics. 10. Clinically significant abnormalities of hematology or chemistry testing at screening visit that the Investigator believes may interfere with the assessment of safety and/or efficacy of the study treatment. 11. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol, in the opinion of the Investigator